Image source: Getty Images.
Earlier this year, GW Pharmaceuticals (NASDAQ: GWPH) stock rallied on clinical success with its cannabis-derived epilepsy treatment. After falling more than 40% in the first months of 2016, the volatile marijuana stock is up about 16% year to date.